An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 30 May 2014
At a glance
- Drugs IC 47 (Primary) ; Aluminium hydroxide
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Intercell
- 28 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2010 Results reported by Intercell.